Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-06-24 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Lynparza approved in China for prostate cancer
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '24 June 2021'. It announces a specific corporate event: the conditional approval of Lynparza in China for prostate cancer treatment. The text concludes with standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority, and ends with 'END'. This structure is characteristic of a regulatory news service announcement, which is a general category for official, timely disclosures that don't fit into more specific financial report types (like 10-K, ER, or IR). Since it is a specific announcement of regulatory/market-moving news distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2021-06-24 English
ORPATHYS APPROVED IN CHINA FOR LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Orpathys in China for lung cancer treatment, including clinical trial results, drug description, and company collaboration details. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a significant corporate event (drug approval) but does not fit into categories like M&A, capital update, or governance. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are periodic reports submitted by foreign private issuers to the SEC to disclose material information. The document length (13,239 characters) and content confirm it is a full Form 6-K report, not just an announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-06-23 English
Orpathys approved in China for lung cancer
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 8162C' and is dated '23 June 2021'. It announces a specific regulatory event: 'Orpathys approved in China for patients with lung cancer and MET gene alterations'. This is a material announcement regarding a drug approval by a regulatory body (NMPA in China). The content is a press release detailing the approval, clinical data, and management commentary, which is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement that doesn't fit the definitions for 10-K, IR, or CT, and it is not merely announcing the publication of a report (RPA), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a financial period, but the focus here is regulatory/product news. Given the structure and the explicit RNS header, RNS is the most appropriate general category for significant, non-standard regulatory news releases.
2021-06-23 English
KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The content primarily announces the approval of Koselugo in the EU for children with neurofibromatosis type 1, including clinical trial results and background information about the drug and disease. There are no financial statements or detailed financial performance data included. The document is an announcement of a regulatory and product approval event rather than a financial report or earnings release. Form 6-K filings typically serve as current reports for foreign issuers to disclose material information. Given the nature and content, this filing best fits the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-22 English
Koselugo approved in the EU for children with NF1
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 6683C' and contains a date stamp '22 June 2021 07:00 BST'. The content describes a regulatory approval ('Koselugo approved in the EU') and includes quotes from company executives and scientific data. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory news service announcement, which fits the definition of 'Regulatory Filings' (RNS) as a broad category for official announcements not covered by more specific codes like 10-K, ER, or DIV. Since it is an announcement of a regulatory event (EU approval) distributed via the RNS system, RNS is the most appropriate classification.
2021-06-22 English
UPDATE ON AZD7442 STORM CHASER TRIAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the AZD7442 STORM CHASER trial, including trial results, safety, efficacy, and financial considerations. The document is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing used to disclose material information to the SEC and investors. The document length is 14,268 characters, which is substantial but typical for a 6-K. The content focuses on clinical trial results and related information rather than financial statements or governance changes. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-15 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.